Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
JANSSEN NZ LIMITED,Fixed duration Ibrutinib plus venetoclax,previously untreated Chronic Lymphocytic Leukaemia (CLL) or Small Lymphocytic Leukaemia (SLL) patients without TP53 mutation,Fixed duration Ibrutinib plus venetoclax (IMBRUVICA),Community and Hospital,
